TranScrip Partners Announce US Expansion

TranScrip Partners, the cutting edge contract organisation, announces opening of US office to better service global client base

PHILADEPHIA--TranScrip Partners, the rapidly growing, cutting-edge contract organisation today announced the formation of its US office, TranScrip Partners (USA) LLC. The US branch of TranScrip Partners will be led by Glenn Tillotson, a pharmaceutical expert with 25 years' industry experience and a successful track record in drug development and life cycle management. The expansion of EU-based TranScrip Partners to the US follows the opening of offices in Australia late last year. The launch of the US office marks an important milestone in the expansion of TranScrip Partners. "Establishing TranScrip's presence in the US will allow us to better support our clients and their global drug development programmes and will add to the depth and breadth of our expertise in drug development and commercialisation", said TranScrip's Managing Partner Dr Flic Gabbay.

TranScrip Partners supports biopharmaceutical product development and life-cycle management across a client base of over 80 companies. TranScrip Partners challenges the traditional CRO model by offering to clients both top-level therapeutic expertise in overcoming the hurdles encountered from translational medicine to successful registration and market access and the staff to support the projects. Services offered by TranScrip Partners include development and market positioning strategies for early molecules as well as tailored support in drug development, medical affairs, pharmacovigilance, regulatory and medical writing during pre and post-approval.

The unique "one-stop shop", character of its organisational model, offers an innovative solution to managing the ever increasing costs of fixed overheads in Pharmaceutical R&D.

TranScrip Partners is a rapidly growing cutting-edge contract organisation that supports biopharmaceutical product development and life cycle management. TranScrip Partners are strategic thinkers that do, and doers who think strategically.

Working for more than 80 companies across four continents, TranScrip challenges the traditional CRO model by championing medicinal products and overcoming the hurdles encountered from translational medicine to successful registration and market access.

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.